Effects of eight weeks aerobic training on levels of amyloid β42, neprilysin and γ- secretase in the hippocampus of male rat Alzheimer’s model by homocysteine injection

References

• 1.
  Souza LC, Filho CB, Goes AT, Fabbro LD, de Gomes MG, Savegnago L, et al. Neuroprotective effect of physical exercise in a mouse model of Alzheimers disease induced by -amyloid140 peptide. Neurotox Res 2013; 24: 148-163.
• 2.
  Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
• 3.
  Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
• 4.
  Cascalheira JF, Joo SS, Pinhanos SS, Castro R, Palmeira M, Almeida S, et al. Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. Clin Biochem 2009; 42: 783-790.
• 5.
  Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 2006; 22: 651-656.
• 6.
  Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275: 630-631.
• 7.
  Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23: 542-549.
• 8.
  Fraser ON, Bugnyar T. Ravens reconcile after aggressive conflicts with valuable partners. PLoS One 2011; 6: e18118.
• 9.
  Pearson HA, Peers C. Physiological roles for amyloid beta peptides. J Physiol 2006; 575: 5-10.
• 10.
  Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, et al. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 1993; 361: 260-263.
• 11.
  Wilson CA, Doms RW, Lee VM. Intracellular APP processing and A [beta] production in Alzheimer disease. J Neuropathol Exp Neurol 1999; 58: 787-794.
• 12.
  Zafra F, Lindholm D, Castren E, Hartikka J, Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J Neurosci 1992; 12: 4793-4799.
• 13.
  Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and A clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimers disease. Front Aging Neurosci 2013; 5: 98.
• 14.
  Nalivaeva NN, Belyaev ND, Zhuravin IA, Turner AJ. The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? Int J Alzheimers Dis 2012; 2012: 383796.
• 15.
  Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552.
• 16.
  Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer's disease? Annu Rev Public Health 2003; 24: 111-132.
• 17.
  Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A 2001; 98: 3440-3445.
• 18.
  Kang EB, Cho JY. Effects of treadmill exercise on brain insulin signaling and -amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. J Exerc Nutrition Biochem 2014; 18: 89-96.
• 19.
  Liu HL, Zhao G, Zhang H, Shi LD. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. Behav Brain Res 2013; 256: 261-272.
• 20.
  Yuede CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, et al. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2009; 35: 426-432.
• 21.
  Hosseinzadeh S, Dabidi Roshan V, Pourasghar M. Effects of intermittent aerobic training on passive avoidance test (shuttle box) and stress markers in the dorsal hippocampus of wistar rats exposed to administration of homocysteine. Iran J Psychiatry Behav Sci 2013; 7: 37-44.
• 22.
  Ataie A, Sabetkasaei M, Haghparast A, Moghaddam AH, Kazeminejad B. Neuroprotective effects of the polyphenolic antioxidant agent, Curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol Biochem Behav 2010; 96: 378-385.
• 23.
  Chilibeck PD, Bell GJ, Farrar RP, Martin TP. Higher mitochondrial fatty acid oxidation following intermittent versus continuous endurance exercise training. Can J Physiol Pharmacol 1998; 76: 891-894.
• 24.
  Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
• 25.
  Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, et al. Blood inflammatory markers and risk of dementia: the conselice study of brain aging. Neurobiol Aging 2007; 28: 1810-1820.
• 26.
  Zylberstein DE, Lissner L, Bjrkelund C, Mehlig K, Thelle DS, Gustafson D, et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging 2011; 32: 380-386.
• 27.
  Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 2007; 27: 2751-2759.
• 28.
  Uslu S, Akarkarasu ZE, Ozbabalik D, Ozkan S, olak O, Demirkan ES, et al. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimers disease and vascular dementia. Neurochem Res 2012; 37: 1554-1559.
• 29.
  Shea YF, Ha J, Chu LW. Comparisons of clinical symptoms in biomarkerconfirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic. Psychogeriatrics 2014.
• 30.
  Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
• 31.
  Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, et al. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol Med 2008; 22: 529-539.
• 32.
  Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 2006; 26: 4277-4288.
• 33.
  Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25: 4217-4221.
• 34.
  Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, et al. Environmental enrichment reduces A levels and amyloid deposition in transgenic mice. Cell 2005; 120: 701-713.
• 35.
  Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002; 25: 295-301.
• 36.
  Lu B, Chow A. Neurotrophins and hippocampal synaptic transmission and plasticity. J Neurosci Res 1999; 58: 76-87.
• 37.
  Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimers disease. J Alzheimers Dis 2010; 22: 569-579.
• 38.
  Trejo JL, Carro E, Torres-Alemn I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 2001; 21: 1628-1634.
• 39.
  Somani SM, Ravi R, Rybak L. Effect of exercise training on antioxidant system in brain regions of rat. Pharmacol Biochem Behav 1995; 50: 635-639.